Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd., Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue “Clinical Pharmaceuticals for Adabelimab injections, SHR-8068 injections, bevacizumab injections, SHR-1826 for injections, SHR-A1904 for injections, and SHR-A2102 for injections “Trial Approval Notice”. Clinical trials will be carried out in the near future.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Hengrui Pharmaceutical (600276.SH) issued an announcement. Recently, the company's subsidiaries Shanghai Shengdi Pharmaceutical Co., Ltd., Suzhou Shengdia Biomedical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue “Clinical Pharmaceuticals for Adabelimab injections, SHR-8068 injections, bevacizumab injections, SHR-1826 for injections, SHR-A1904 for injections, and SHR-A2102 for injections “Trial Approval Notice”. Clinical trials will be carried out in the near future.